174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML

✍ Scribed by A. Ganser; W.K. Hofmann; G. Geissler; O.G. Ottmann; J.Th. Fischer; G. Heil; W. Heit; W. Langer; F. Herrmann; U. Kiehntopf; A. Knuth; K. Höffken; K. Hoffmann; C. Huber; K. Kolbe; H.J. Schmoll; T. Buechele; B. Hertenstein; D. Hoelzer

• Book ID: 114119392
• Publisher: Elsevier Science
• Year: 1997
• Tongue: English
• Weight: 123 KB
• Volume: 21
• Category: Article
• ISSN: 0145-2126
• DOI: 10.1016/s0145-2126(97)81413-0